Diagnostic Company LumiraDX Goes Public In $5Bn SPAC Merger
LumiraDX secured $400m in new debt financing and will use all proceeds to fund growth.
You may also be interested in...
The SPAC deal between CM Life Sciences II and SomaLogic is valued at $1.25bn.
As the SPAC boom continues, innovative medtechs are expected to become acquisition targets.
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.